HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stomach cancer: targeted drug combo trial launches
Disease control Recruiting nowThis study tests a drug called trastuzumab deruxtecan (T-DXd), alone or with chemotherapy and immunotherapy, in people with advanced HER2-positive stomach or esophageal cancer. The goal is to see if these combinations are safe and can shrink tumors. About 450 adults with cancer t…
Matched conditions: HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Cancer drug enhertu gets a shot in the arm: new Under-the-Skin version tested
Disease control Recruiting nowThis early-phase trial is testing a new way to give the cancer drug T-DXd (Enhertu) — as a shot under the skin instead of an IV drip. The study will enroll 76 adults with metastatic solid tumors to find the safest dose and see how well the body handles it. Researchers will also c…
Matched conditions: HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug under Real-World watch for tough stomach cancer
Disease control Recruiting nowThis study follows about 257 adults with advanced HER2-positive stomach or gastroesophageal junction cancer who have already tried a trastuzumab-based treatment. Researchers will track how well the drug trastuzumab deruxtecan (T-DXd) works in everyday medical practice, including …
Matched conditions: HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC